Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.

Detailed Description
-----------------
All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.

Official Title
-----------------
Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection

Conditions
-----------------
Hepatitis, Hepatitis B, Lymphoma, Hematologic Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: treatment-naive patients with lymphoma patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or hepatitis B core antibody (anti-HBc) positive Exclusion Criteria: HBsAg and HBcAb negative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| group with HBV reactivation<br>group with hepatitis B virus reactivation | |
| group without HBV reactivation<br>group without hepatitis B virus reactivation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of hepatitis B virus delayed reactivation | hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy | within one year after withdrawal of prophylactic antiviral therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of hepatitis B virus related hepatitis flare | the incidence of hepatitis B virus related hepatitis flare after withdrawal of prophylactic antiviral therapy | within one year after withdrawal of prophylactic antiviral therapy | 
| Number of patients that achieve a tumor response |  | within one year after withdrawal of prophylactic antiviral therapy | 
| overall survival rate |  | within one year after withdrawal of prophylactic antiviral therapy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hepatitis, hepatitis B, lymphoma, Hematologic Diseases